Fig 1: Vδ1/3 T cells respond to IV-BCG earlier than CD8 T cellsBackground-subtracted frequency of CD8, Vγ9+, and Vδ1/3+ T cell subsets in PBMCs expressing (A) CD137, (B) granzymes (GZMB or GZMK), (C) CD107a, and (D) cytokine (IFN-γ or TNF) after stimulation with Mtb whole-cell lysate among IV-BCG-vaccinated (n = 16) and unvaccinated (n = 9) rhesus macaques. Median frequencies are plotted pre-vaccination (Pre) and at week 2 (W2), week 4 (W4), and week 8 (W8) post IV-BCG. The frequency of Vγ9+ γδ T cells or CD8 T cells is compared to the frequency of Vδ1/3 T cells at each time point. Background-subtracted frequency of CD8, Vγ9+, and Vδ1/3+ T cell subsets in BAL expressing (E) CD137, (F) granzymes (GZMB or GZMK), (G) CD107a, and (H) cytokine (IFN-γ or TNF) after stimulation with Mtb whole-cell lysate. Boxplots compare median and interquartile range within unvaccinated macaques (Unvax) and at week 8 (W8) post-vaccination. Statistical testing was performed using a paired Wilcoxon signed-rank test. Unadjusted p values are displayed.
Supplier Page from Novus Biologicals, a Bio-Techne Brand for CD8 Antibody (2ST8.5H7) - Azide Free
Available conjugates: Available conjugates: UnconjugatedSpecificity: CD8 Antibody (2ST8.5H7) recognizes the human CD8 cell surface antigen. The antibody binds to the beta chain, recognizing an epitope that is dependent upon expression of both CD8 alpha and CD8 beta. CD8 molecules are composed of dimers of either alpha/alpha or alpha/beta polypeptide combinations. Both types of dimer may co-exist at the cell surface.Sizes Available: 0.1 mg (also 0.025 mg)